Application of ceruloplasmin

Abstract

The invention belongs to the field of biological medicine application, and particularly relates to application of ceruloplasmin in preparing medicines for preventing or / and relieving or / and treating Alzheimer's disease, or / and the application of the ceruloplasmin in the aspects of preparing educational supplements or medicines. According to the application of the ceruloplasmin, the ceruloplasmin can play roles of enhancing memory ability and improving a cognitive function. The inventor finds that the ceruloplasmin can significantly promote growth of nerve cells, and can significantly improve the learning and memory ability of a dementia animal model. A cell experiment result indicates that the ceruloplasmin can effectively restrain damage of A[beta] on nerve cells, and has a protective effect for the nerve cells. A nesting experiment result indicates that the ceruloplasmin can improve the nesting ability of the dementia animal model, and reminds improvement of self-care ability of dementia animals. A maze experiment result indicates that the ceruloplasmin can improve the learning and memory ability of the dementia animal model.

Description

technical field [0001] The present invention belongs to the application field of biological medicines, and in particular relates to the application of ceruloplasmin in the preparation of drugs for preventing or / and improving or / and treating Alzheimer's disease; or / and the application of ceruloplasmin in the preparation of intellectual supplements or drugs aspects of application. Background technique [0002] Alzheimer's disease (Alzheimer's disease, AD), also known as senile dementia, is a degenerative disease of the brain and central nervous system caused by neuron loss, and the incidence of the disease in the elderly population is about 4%-8%. . In 1906, the German neuropathologist Alzheimer first reported a 51-year-old female patient with progressive memory loss. In 1910, psychiatrist Emil Kraepelin, known for naming and categorizing brain disorders, proposed the name Alzheimer's disease. The common clinical manifestations of the disease are progressive memory and cogn...

AI Technical Summary

Problems solved by technology

The pathogenesis of AD is complex, including amyloid deposition, the dynamic imbalance of metal ions in the brain, the reduction of neurotransmitters and neuronal apoptosis caused by mitochondrial dysfunction, etc., involving a variety of molecular signaling pathways. Currently, there are only 4 therapeutic drugs on the market. All of them (donepezil, galantamine, rivastigmine, and memantine) are mainly used to delay the progression of early AD symptoms and improve the clinical symptoms of early AD. So far, there is no effective drug to reverse or prevent the progression of the disease

Images